Clinical efficacy of sacubitril-valsartan in patients with acute myocardial infarction complicated with mitral regurgitation

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054255

Enrollment

Unknown

Registered

2021-12-11

Start date

2021-06-16

Completion date

Unknown

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction

Interventions

Experimental group:sacubitril valsartan

Control group:benazepril

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with first acute myocardial infarction receiving PCI or patients with acute myocardial infarction coronary angiography showing mild to moderate stenosis of the culprit vessel; 2. Echocardiography within 3 days of hospitalization indicates ''segmental myocardial abnormality and mitral regurgitation (moderate or more regurgitation)''; 3. Informed consent, able to cooperate with follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of heart valve disease or heart surgery; 2. Patients with acute myocardial infarction complicated by chordae tendineae rupture, mitral valve prolapse and other complications; 3. Patients with severe liver, kidney and lung insufficiency, moderate to severe anemia, hyperthyroidism, severe bilateral renal artery stenosis, angioedema and a history of malignant tumors; 4. Patients with refractory hypotension (90/60mmHg) and patients with refractory hyperkalemia.

Design outcomes

Primary

Measure	Time frame
Mitral regurgitation;N-terminal B-type natriuretic peptide precursor;Cardiovascular major adverse events;Ejection fraction;Cardiac index;	—

Countries

China

Contacts

Public ContactYin Hongtao

Qinhuangdao First Hospital

289750320@qq.com+86 18133509982

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026